Papazian, Irini
Tsoukala, Eleni
Boutou, Athena
Karamita, Maria
Kambas, Konstantinos
Iliopoulou, Lida
Fischer, Roman
Kontermann, Roland E.
Denis, Maria C.
Kollias, George
Lassmann, Hans
Probert, Lesley
Funding for this research was provided by:
Management and Implementation Authority for Research, Technological Development and Innovation Actions (MIA-RTDI/ ΕΥΔΕ-ΕΤΑΚ) of the Hellenic Ministry of Development and Investments (T1EDK-01859)
Article History
Received: 23 December 2020
Accepted: 20 April 2021
First Online: 26 September 2021
Declarations
:
: The animal study was reviewed and approved by the Committee for Evaluation of Experimental Procedures, Department of Experimental Animal Models, Hellenic Pasteur Institute (Presided by Dr. P. Andriopoulos, pandriopoulos@patt.gov.gr, for the Hellenic Republic, General Secretariat for Agricultural Economy, Veterinary and Licenses). License numbers 4457/10-07-2014 and 2579/31-05-2018
: Not applicable.
: RF and REK are named inventors on patent applications covering the TNFR2 agonist technology. The other authors declare that they have no competing interests.